WO1997015553A1 - Hyroxamic acid derivatives - Google Patents

Hyroxamic acid derivatives Download PDF

Info

Publication number
WO1997015553A1
WO1997015553A1 PCT/JP1996/003077 JP9603077W WO9715553A1 WO 1997015553 A1 WO1997015553 A1 WO 1997015553A1 JP 9603077 W JP9603077 W JP 9603077W WO 9715553 A1 WO9715553 A1 WO 9715553A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
acid derivatives
represents hydrogen
hyroxamic acid
hyroxamic
Prior art date
Application number
PCT/JP1996/003077
Other languages
French (fr)
Japanese (ja)
Inventor
Tomoyuki Shibata
Nobuyuki Ohkawa
Toshiyasu Takemoto
Kazuhiko Tamaki
Shinwa Kurihara
Susumu Sato
Kazuhiko Tanzawa
Tomowo Kobayashi
Kosaku Fujiwara
Original Assignee
Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Company, Limited filed Critical Sankyo Company, Limited
Priority to AU73354/96A priority Critical patent/AU7335496A/en
Publication of WO1997015553A1 publication Critical patent/WO1997015553A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Hydroxamic acid derivatives represented by general formula (1) or pharmacologically acceptable salts thereof which are excellent in the inhibitory activity on matrix metaproteinase and useful as a preventive and remedy for metastatic infiltration or multiplication of various cancer cells, arthrosis deformans, etc., wherein R1 represents C¿1-4? alkyl, etc.; R?2 and R3¿ independently represent each optionally substituted C¿1-4? alkyl, etc.; R?4¿ represents C¿8-10? alkyl; R?5¿ represents hydrogen, etc.; and R6 represents hydrogen, etc..
PCT/JP1996/003077 1995-10-23 1996-10-23 Hyroxamic acid derivatives WO1997015553A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU73354/96A AU7335496A (en) 1995-10-23 1996-10-23 Hyroxamic acid derivatives

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP27382695 1995-10-23
JP7/273826 1995-10-23
JP19048296 1996-07-19
JP8/190482 1996-07-19

Publications (1)

Publication Number Publication Date
WO1997015553A1 true WO1997015553A1 (en) 1997-05-01

Family

ID=26506117

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1996/003077 WO1997015553A1 (en) 1995-10-23 1996-10-23 Hyroxamic acid derivatives

Country Status (2)

Country Link
AU (1) AU7335496A (en)
WO (1) WO1997015553A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055449A1 (en) * 1997-06-06 1998-12-10 The University Of Queensland Hydroxamic acid compounds having anticancer and anti-parasitic properties
WO1999067201A1 (en) * 1998-06-22 1999-12-29 Smithkline Beecham Plc Hydroxamic acid derivatives as inhibitors of the production of human cd23 and of the tnf release
WO2002006227A1 (en) * 2000-07-18 2002-01-24 Chugai Seiyaku Kabushiki Kaisha Matrix metalloprotease inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019961A1 (en) * 1994-01-22 1995-07-27 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
WO1996016931A1 (en) * 1994-11-26 1996-06-06 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
WO1996033166A1 (en) * 1995-04-18 1996-10-24 The Du Pont Merck Pharmaceutical Company Hydroxamic and carboxylic acids as metalloprotease inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019961A1 (en) * 1994-01-22 1995-07-27 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
WO1996016931A1 (en) * 1994-11-26 1996-06-06 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
WO1996033166A1 (en) * 1995-04-18 1996-10-24 The Du Pont Merck Pharmaceutical Company Hydroxamic and carboxylic acids as metalloprotease inhibitors

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055449A1 (en) * 1997-06-06 1998-12-10 The University Of Queensland Hydroxamic acid compounds having anticancer and anti-parasitic properties
WO1999067201A1 (en) * 1998-06-22 1999-12-29 Smithkline Beecham Plc Hydroxamic acid derivatives as inhibitors of the production of human cd23 and of the tnf release
US6458779B1 (en) 1998-06-22 2002-10-01 Smithkline Beecham P.L.C. Hydroxamic acid derivatives as inhibitors of the production of human CD23 and of the TNF release
WO2002006227A1 (en) * 2000-07-18 2002-01-24 Chugai Seiyaku Kabushiki Kaisha Matrix metalloprotease inhibitors

Also Published As

Publication number Publication date
AU7335496A (en) 1997-05-15

Similar Documents

Publication Publication Date Title
WO2000004014A1 (en) Pyrimidine derivatives exhibiting antitumor activity
EP0758653A4 (en) Imidazoquinazoline derivatives
EP1070714A4 (en) Amidine compounds
EP1043324A4 (en) Purine derivatives and medicine containing the same as the active ingredient
CA2260337A1 (en) Therapeutic agents
CA2273841A1 (en) 3-thiocarbamoylpyrazole derivatives as pesticides
TR200002191T2 (en) Potassium channel inhibitors
RS49688B (en) New 3-aryl-2-hydroxypropionic acid derivative (i)
EP1302462A4 (en) Sulfone derivatives, process for their production and use thereof
CA2270964A1 (en) Benzonaphthyridines as bronchial therapeutics
NO982987D0 (en) Amidinoproteasehemmere
TW376382B (en) Arylcycloalkyl derivatives for against inflammatory conditions
CA2208792A1 (en) Substituted indazole derivatives
AU5970199A (en) Benzonaphthyridine-n-oxides comprising a pde3 and pde4 inhibiting activity
WO2000005214A3 (en) Isoquinolines as urokinase inhibitors
CA2322689A1 (en) Substituted bisindolymaleimides for the inhibition of cell proliferation
CA2087859A1 (en) Benzopyran derivatives
NO981393D0 (en) Guanidinoproteasehemmere
CA2317604A1 (en) Matrix metalloprotease inhibitors
IE42977L (en) Triaryl-piperidine methanols.
WO1997015553A1 (en) Hyroxamic acid derivatives
MY132057A (en) Quinoxalinones, a process for their preparation and their use
EP0972808A4 (en) Composition containing dithiocarbonate compound
TR199701202T1 (en) New hydroxymic acid derivatives.
EP1074545A4 (en) Isoquinolinesulfonamide derivatives and drugs containing the same as the active ingredient

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN CZ HU KR MX NO NZ RU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA